

PATENT

1623
1651

Case Docket No. HORI3.001AUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hahn, et al.
Appl. No. : 09/965,126
Filed : September 26, 2001
For : METHOD OF MEASURING
CERULOPLASMIN
CONCENTRATION IN A
BLOOD SPOT, KIT AND
METHOD OF DIAGNOSING
WILSON'S DISEASE
Examiner : Unknown
Group Art Unit : 1623

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

10/28/03
(Date)

Mincheol Kim, Reg. No. 51,306

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with 2 references.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Mincheol Kim
Registration No. 51,306
Agent of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicants	:	Hahn, et al.
App. No.	:	09/965, 126
Filed	:	September 26, 2001
For	:	METHOD OF MEASURING CERULOPLASMIN CONCENTRATION IN A BLOOD SPOT, KIT AND METHOD OF DIAGNOSING WILSON'S DISEASE
Examiner	:	Unknown
Group Art Unit	:	1623

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing two references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months days/months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/28/03

By: 

Mincheol Kim
Registration No. 51,306
Agent of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
HORI3.001AUSAPPLICATION NO.
09/965,126INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Hahn, et al.FILING DATE
September 26, 2001GROUP
1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Ohura, et al., "Pilot study of screening for Wilson disease using dried blood spots obtained from children seen at outpatient clinics" 1994, J. Inher. Metab. Dis. 22, pages 74-80.
	Hiyamuta, et al., "Monoclonal Antibody Against the Active Site of Caeruloplasmin and the ELISA System Detecting Active Caeruloplasmin" 1994, Hybridoma, Vol. 13(2), pages 139-141.

S:\DOCS\MCK\MCK-8056.DOC
102203

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.